You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 23, 2019

Vietnam Investment Review: CPTPP Obligations Alter Vietnam’s IP Landscape

Subscribe to Updates
Vietnam Investment Review (VIR)

Due to significant changes to the intellectual property (IP) landscape, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) indeed poses major challenges to Vietnam in implementing its obligations. Most of the obligations aim to enhance protection for IP proprietors. This will have a particular impact on the life science sectors, benefitting foreign pharmaceutical and agrochemical companies but reducing opportunities, at least in the short-term, for Vietnamese companies.

The obligations under the CPTPP are widespread. The IP chapter of the agreement is the only chapter with obligations affecting both CPTPP members and other member countries of the World Trade Organization. Non-bloc countries with strong IP-based economies such as the EU and the US still enjoy protection at the same level as other CPTPP members.

Vietnam is turning to Industry 4.0 to drive the economy forward, and some Vietnamese companies are now developing IP-oriented products. Thus, as IP serves as an engine for the economy, Vietnam should make the most of the opportunity the CPTPP affords across various areas, including those set out below.

Enforcement

Under the CPTPP, Vietnam must boost the effectiveness of its fight against IP infringement. To this end, Vietnam must assume responsibility for making the enforcement system more transparent and equitable, guaranteeing public access to all its rulings. More significantly, Vietnam must additionally criminalise some IP offenses such as wilful import or export of counterfeit trademark goods or pirated copyright goods, wilful import and domestic use of counterfeit labels or packaging, recording, and trade secret infringement.

Pursuant to a resolution of the National Assembly, Vietnam will amend the prevailing Penal Code in the next three years to codify these crimes. Vietnam would also leave out the requirement for a complaint from the IP owner to take criminal action against counterfeiting.

Regarding border control, the CPTPP requires that a right holder be provided with specific information about a shipment at issue. The CPTPP also allows an ex officio seizure of counterfeits in transit, in a two-year transition, and exports in a three-year transition.

This regulation clears up the doubt whether export of goods could constitute IP infringement. The regulation will also nullify the current relevant provision of the Law on Customs, which spares goods in transit from sanctions.

The pact also requires Vietnam to either pinpoint statutory damages or provide for punitive damages. Currently, no punitive damages are available in Vietnam. As to statutory damages, Article 205.1(c) of the Law on Intellectual Property allows the plaintiff to claim damages, which are capped at VND500 million ($21,739). However, to this end, in addition to the rationale for the claim, the plaintiff must prove that it cannot establish the actual damages. Thus, in fact, this provision has never been effective in practice, and on balance of convenience, courts often refuse to apply the provision.

Trademarks

Under the CPTPP, within three years, Vietnam must set up a mechanism to register sound trademarks, and do its best to register scent trademarks. Currently, the country only protects visible trademarks.

The country must also revisit its approach in recognising the well-known status of a trademark. Currently, authorities acknowledge the well-known status of a mark only if the mark acquires a very high degree of public knowledge from almost every walk of life, a practice that conflicts with the commitments in the CPTPP.

Licence Recordal

The CPTPP eliminates the requirement for registering a trademark licence to establish the validity of such licence against a third party. The draft bill emphasises this elimination, and also sets out that the use of the trademark by the licencee would inure to the benefit of the trademark owner. However, the bill does not specify whether the use of the trademark by companies economically related to the trademark owner, such as affiliates and subsidiaries, also amounts to authorised use.

Licences for other registered IP such as patents still need to be registered to be enforceable against a third party. This presents hurdles to business transactions due to the vague definition of the term “third party”. Any entity other than the signatories, including banks and tax authorities, can claim to be the third party to such license agreement, which may complicate the performance of obligations under unregistered licences.

Domain Name Disputes

Currently, domain name dispute resolution is itself a matter of dispute between duelling authorities. The Ministry of Science and Technology, which administers IP matters, and the Ministry of Information and Communication (MIC), which administers internet matters, have thus far been unable to reach an agreement to set up effective regimes for resolving disputes involving country code top-level domains.

The CPTPP requires Vietnam to set up such a regime. In line with this provision, the National Assembly passed a resolution to require an amendment to Article 130.1(d) on cybersquatting of the Law on Intellectual Property. However, the draft bill does not set out the amendment. Rather, the Ministry of Industry and Trade, which took charge of drafting the bill, recommended the MIC revise the relevant provisions in Decree No.72/2013/ND-CP to reflect the CPTPP’s requirement.

It seems that the battle of domain name disputes between the two ministries still lingers.

Other IP Subject Matters

The CPTPP significantly expands the grace period for patent novelty, from six months to 12 months. Vietnam will need to extend the exceptions for determining novelty when assessing the patentability of an invention. The agreement also alludes to protection of geographical indications, especially in connection with trademarks, and affords protection to the translation or transliteration of geographical indications.

Commitments to Specific Industries

In the agrochemical industry, Vietnam must ensure data exclusivity for undisclosed clinical trial data or other data for agricultural products for 10 years.

Particularly, Vietnam’s regulatory agency must not grant marketing approval to unauthorised parties, for example generic manufacturers, based on data concerning the safety and efficacy of an approved product that has been submitted by other parties in either Vietnam or in other countries. Vietnam has a 10-year transition period to implement this obligation.

In the pharmaceutical sector, Vietnam must also establish a patent linkage system in connection with the marketing approval process.

Balance of Enforcement

The CPTPP seems to create more balanced treatment for entities accused of IP infringement. When the court does not find infringement, the court can award the defendant reasonable legal fees that it spends for the suit. Under the prevailing Law on Intellectual Property, only the plaintiff is entitled to such legal fee award.

In addition, the pact also allows Vietnam to punish the abuse of IP rights by the owner. The draft bill supplements Article 198 of the prevailing Law on Intellectual Property to lay down such regulation. However, the supplemented article does not go into detail about how to determine the abuse.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
Read More
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
Read More
June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
Read More
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
Read More